Mapping of Clinical Interventions for EGFR Inhibitor-associated Dermatologic Toxicities

A total of 26 clinical studies that evaluated preventive or therapeutic interventions for EGFR inhibitor-associated dermatological toxicities were included. Most of these studies were RCTs, including phase III studies, indicating a relatively well-developed evidence base. Acneiform rash was the most frequently investigated toxicity, followed by pruritus and paronychia (Table 1).

Table 1 EGFR inhibitor-associated dermatologic interventions (n = 26)Comprehensive Tetracycline- or Macrolide-based Prophylactic Regimens

Multicomponent prophylactic strategies that combine systemic tetracyclines (minocycline, tetracycline, or doxycycline) with topical corticosteroids and skin barrier care have demonstrated the most consistent reductions in moderate-to-severe dermatological toxicities.

In the STEPP trial [3], grade ≥ 2 skin toxicities decreased from 62% in the reactive management group to 29% in the preemptive group. Similarly, the J-STEPP study [9] reported a reduction in grade ≥ 2 toxicities from 62.5 to 21.3%. A phase III randomized trial of clarithromycin prophylaxis [10] reported reductions in grade ≥ 2 skin toxicities from 54.7 to 21.3%. Recently, the global COCOON trial [6] showed that enhanced prophylactic dermatologic management reduced grade ≥ 2 adverse events from 75 to 42% without preventive topical corticosteroid administration.

Tetracycline or Macrolide Monotherapy

A randomized placebo-controlled trial of tetracycline [11] showed no significant reduction in grade ≥ 2 rash. A double-blind trial of minocycline [12] demonstrated significantly reduced facial lesion counts during weeks 1–4, but no sustained effect at week 8. In the Pan-Canadian Rash Trial [13], minocycline did not significantly reduce the overall incidence of rash, although a reduction in grade 3 events was observed (12 to 28%).

Topical Antibiotic Strategies

A double-blind randomized trial of topical doxycycline 4% foam [14] demonstrated a reduction in moderate-to-severe rash severity, although the overall incidence reduction was not clearly determined.

Vitamin K–based Modulation of EGFR Signaling

Topical vitamin K-based strategies yielded inconsistent results. A pilot study [15] suggested reduced occurrence of grade 3 rashes compared with historical controls. However, in the EVITA trial [16], vitamin K1 showed no reduction in grade ≥ 2 rash incidence, although severity scores improved. A subsequent double-blind randomized study [17] found no significant benefits.

Repair-oriented Therapy (Epidermal Growth Factor-based Approaches)

A phase II study of epidermal growth factor (EGF) ointment [18] reported a 69% response rate in patients with established rash. A subsequent phase III randomized trial [19] demonstrated a dose-dependent response, with 77.8% response rate in the high-dose EGF group compared to that of 44.4% in the placebo group (p = 0.042). However, these studies were not designed with adequately powered sample sizes.

Neurokinin-1 Receptor Antagonists for Pruritus

Three studies evaluated the use of neurokinin-1 (NK1) receptor antagonists for EGFR-TKI-associated pruritus. A single-arm pilot study on aprepitant [20] demonstrated substantial symptom reduction. A placebo-controlled randomized trial of orvepitant [21] demonstrated no superiority over the placebo. In contrast, a double-blind randomized trial comparing aprepitant with desloratadine [22] showed significantly higher response rates with aprepitant (53 vs. 24%).

Anti-inflammatory Modulation with NSAIDs

Two retrospective cohort studies evaluated the use of NSAIDs for EGFR inhibitor-associated rash. In EGFR-TKI-treated patients [23], NSAID co-administration was associated with reduced risk of rash (adjusted Hazard Ratio [HR], 0.149). Similarly, in patients with panitumumab-treated colorectal cancer [24], the use of NSAIDs reduced grade ≥ 2 rash incidence (78% vs. 90.7%; Odds Ratio [OR], 0.2).

Topical β-blockers for Paronychia

Paronychia-specific strategies have been studied less frequently. Prophylactic topical betaxolol [25] reduced the incidence of paronychia from 58 to 20%. Treatment with topical timolol combined with antibiotics [26] achieved an 83% overall response rate in established lesions.

Mechanism × Outcome Matrix (EGFR Inhibitor-associated Dermatologic Toxicities)

Interventions were categorized according to primary mechanism and mapped against outcome type (Fig. 2). Multi-component tetracycline- or macrolide-based strategies demonstrated the most consistent reduction in grade ≥ 2 dermatological toxicities, as supported by multiple randomized trials [3, 6, 9, 10]. In contrast, tetracycline or macrolide monotherapy exhibited limited reductions in overall incidence but modest effects on severity, particularly in high-grade events [12, 13]. Similarly, topical antibiotic approaches primarily reduced severity rather than incidence [14]. Vitamin K-based interventions showed inconsistent results, with no reproducible reduction in grade ≥ 2 toxicity [16, 17]. EGF-based repair-oriented therapies were effective for established lesions in phase II and III trials [18, 19], whereas NK1 receptor antagonists showed drug-specific variability in pruritus control [21, 22]. Observational data suggested a potential role for NSAIDs in reducing rash incidence across EGFR inhibitor classes [23, 24], and that topical β-blockers were beneficial for periungual toxicities [25, 26]. Overall, the matrix highlights that multi-component prophylactic regimens yielded the most robust incidence reduction, whereas single-mechanism approaches produced selective severity modulation or variable therapeutic responses more frequently.

Fig. 2

Mechanism × outcome matrix of clinical interventions for EGFR inhibitor-associated dermatologic toxicities. This heatmap summarizes the distribution and relative strength of the evidence for preventive and therapeutic strategies targeting EGFR inhibitor-related dermatological adverse events. The horizontal axis represents intervention categories based on clinical strategy, including minocycline/tetracycline/doxycycline combined with topical corticosteroids, antibiotic monotherapy (minocycline/tetracycline/doxycycline), topical antibiotics, vitamin K-based therapy, epidermal growth factor (EGF)-mediated repair, neurokinin-1 (NK1) receptor antagonists, non-steroidal anti-inflammatory drugs (NSAIDs), β-adrenergic blockers, and topical retinoids. The vertical axis represents outcome categories: reduction in incidence of grade ≥ 2 toxicities, reduction in severity without clear incidence reduction, demonstrated treatment efficacy for established toxicities, and interventions with negative or inconclusive results. Color intensity reflects the relative strength of the clinical evidence (0 = no evidence; 1 = weak or inconsistent evidence; 2 = moderate evidence; and 3 = strong evidence, supported by phase III randomized trials). Comprehensive antibiotic-based prophylactic regimens combined with topical corticosteroids consistently demonstrated reductions in moderate-to-severe dermatologic events, whereas single-mechanism approaches frequently showed selective severity modulation or inconsistent findings. Repair-oriented strategies (EGF-based therapy) demonstrated strong therapeutic efficacy for established toxicities

Mapping of Clinical Interventions for Capecitabine-induced HFS

A total of 17 clinical studies that evaluated preventive strategies for capecitabine-induced HFS were included (Table 2). Mechanism-based mapping revealed clear differences in therapeutic efficacy across intervention categories (Fig. 3).

Table 2 Clinical interventions for capecitabine-induced HFS (n = 17)Fig. 3

Mechanism × outcome matrix of clinical interventions for capecitabine-induced hand–foot syndrome (HFS). This heatmap summarizes the distribution and relative strength of the clinical evidence for preventive and therapeutic strategies targeting capecitabine-associated HFS. The horizontal axis represents intervention categories based on the proposed biological mechanisms, including oral and topical NSAIDs, topical corticosteroids, neuroprotective modulation (methylcobalamin), lithium-based barrier reinforcement, vitamin B6 (pyridoxine), keratolytic strategies, antioxidant formulations, structured educational interventions, and herbal medicine (TJ-28). The vertical axis represents the outcome categories: reduction in the incidence of grade ≥ 2 HFS, reduction in severity without consistent incidence reduction, and interventions with no demonstrated benefit. Color intensity reflects the relative strength of the clinical evidence (0 = no evidence; 1 = weak or limited evidence; 2 = moderate evidence; and 3 = strong evidence, supported by phase III randomized trials). Both systemic and topical NSAIDs demonstrated the most consistent reduction in moderate-to-severe HFS. Neuroprotective modulation with methylcobalamin also showed a significant reduction in incidence in a phase III trial. In contrast, vitamin B6, keratolytic formulations, antioxidant ointments, and structured educational interventions consistently failed to demonstrate preventive efficacy across randomized trials

NSAIDs and Anti-inflammatory Strategies

In a randomized phase II study, celecoxib reduced the incidence of grade ≥ 2 HFS from 30 to 11.8% [32]; this benefit was further confirmed in a subsequent phase III randomized trial, in which grade ≥ 2 HFS was reduced from 29.6% to 14.7% [33]. Topical diclofenac treatment yielded similar results. In the D-TORCH phase III trial, topical diclofenac reduced grade ≥ 2 HFS from 15.0% to 3.8% [7].

Neuroprotective Modulation

A multicenter, double-blind phase III trial demonstrated that oral methylcobalamin reduced grade ≥ 2 HFS from 29.1% to 14.5% [34].

Topical Corticosteroids

A phase II study of prophylactic topical hydrocortisone reported a low incidence of grade ≥ 2 HFS (6.4%) within four cycles [8], supporting an inflammatory mechanism, although confirmatory randomized data remain limited.

Lithium-based Barrier Modulation

A double-blind, randomized study of a lithium-containing moisturizing formulation demonstrated a reduction in severe HFS [35], although its effects on overall incidence were modest.

Interventions without Demonstrated Benefit

Vitamin B6 (pyridoxine) showed no reduction in grade ≥ 2 HFS across four randomized trials [36,37,38,39]. Keratolytic agents (including urea and lactic acid) were also ineffective for moderate-to-severe HFS in a phase III trial [40]. Antioxidant ointment (Mapisal) showed no superiority over urea [41]. Structured educational interventions were also ineffective in reducing grade ≥ 2 HFS in a phase III trial [42]. A phase II randomized trial of TJ-28 (a Kampo medicine) also failed to demonstrate preventive efficacy [43].

Mechanism × Outcome Matrix (Capecitabine-induced HFS)

The mechanism × outcome matrix for capecitabine-induced HFS (Fig. 3) indicates that NSAIDs—both systemic and topical—provide the strongest and most consistent reduction in the incidence of grade ≥ 2 HFS. Neuroprotective modulation using methylcobalamin also demonstrated significant benefits in a phase III trial. In contrast, metabolic modulation (vitamin B6), keratolytic approaches, antioxidant formulations, and structured educational strategies were consistently ineffective in reducing clinically significant HFS across several randomized trials. Overall, this matrix suggests that capecitabine-induced HFS is predominantly driven by inflammatory and neuropathic mechanisms rather than by abnormalities in keratinization or metabolic pathways.

Mapping of Clinical Interventions for Multikinase Inhibitor-associated HFSR

Eight clinical studies that evaluated preventive strategies against multikinase inhibitor-associated HFSR were included (Table 3). Mechanism-based mapping revealed a multifactorial therapeutic landscape that differed from that of fluoropyrimidine-associated HFS (Fig. 4).

Table 3 Clinical interventions for multikinase inhibitor-associated HFSR (n = 8)Fig. 4

Mechanism × outcome matrix of interventions for multikinase inhibitor-associated HFSR. Interventions are categorized based on the proposed mechanisms (horizontal axis) and mapped against outcome type (vertical axis: incidence reduction, severity reduction, or no significant benefit). Color intensity reflects the relative strength of the evidence (0 = none; 1 = limited; 2 = phase II; and 3 = phase III). Barrier reinforcement (urea-based strategies), COX-2 inhibition, and preemptive high-potency corticosteroids demonstrated the most consistent reductions in clinically significant HFSR

Barrier Reinforcement Strategies

Barrier reinforcement using intensive urea-based formulations demonstrated strong evidence for incidence reduction. A multicenter, phase III trial demonstrated that prophylactic application of 10% urea cream three times daily significantly reduced any-grade HFSR (73.6% to 56.0%) and grade ≥ 2 events (29.2% to 20.7%) [44]. Conversely, a double-blind randomized trial employing twice-daily urea application showed no benefit for HFSR incidence reduction [45]. Similarly, in a secondary prophylaxis setting during sunitinib therapy, twice-daily urea was not superior to placebo [46].

Friction Reduction

Mechanical offloading through hydrocolloid dressings significantly reduced progression to grade ≥ 2 HFSR in a randomized phase II study, with incidence decreasing from 69% in the urea arm to 29% in the dressing arm [47].

COX-2 Inhibition

Systemic COX-2 inhibition has demonstrated consistent benefits. In a phase III randomized trial, celecoxib reduced grade ≥ 2 HFSR from 63.8% to 29.3% and grade 3 events from 19.0 to 3.4% [48].

High-potency Corticosteroids

Preemptive use of high-potency topical corticosteroids, such as clobetasol, significantly increased the proportion of patients without HFSR during the first two cycles of regorafenib therapy (30% vs. 13%) [49].

Sweat Suppression

A prospective phase II trial of topical aluminum chloride demonstrated a low incidence of grade 3 HFSR (7.4%) compared to that of historical rates (~ 20%), suggesting a potential benefit in reducing severe events [50].

Herbal Anti-inflammatory Modulation

A double-blind randomized trial of TDX105 topical soaking solution significantly reduced the overall incidence of HFSR (76.1% to 53.8%), grade 3 events (19.6% to 7.7%), and delayed onset of HFSR (median, 25 vs. 11 days) during regorafenib therapy [34].

Mechanism × Outcome Matrix (Multikinase Inhibitor-associated HFSR)

The mechanism × outcome matrix for multikinase inhibitor-associated HFSR (Fig. 4) demonstrated that barrier reinforcement (with adequate dosing), systemic COX-2 inhibition, and high-potency corticosteroids provided the most consistent reductions in clinically significant HFSR. Friction reduction and sweat suppression strategies further support the roles of mechanical and eccrine factors in disease development. Collectively, these findings indicate that HFSR arises from the interplay between mechanical stress, epidermal barrier dysfunction, and inflammatory signaling, mechanistically distinguishing it from capecitabine-induced HFS.